Navigation Links
terna Zentaris Discloses First In Vitro Data for its PI3K,,,Inhibitors at the AACR Annual Meeting in Los Angeles

collected. Several derivatives are currently undergoing first pharmacokinetic in vivo studies.

About terna Zentaris Inc.

terna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
Post Your Comments:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... , July 2, 2015  Konica Minolta, Inc. (Konica ... that it has acquired Sawae Technologica Ltda., an X-ray ... Brazil , through its Brazilian healthcare sales company, ... Local Brazil market ... increasing population exceeding 200 million, significant healthcare technical advancements ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, ... and incorrect application of the efficacy assessment protocol. With this ... dyskinesia symptoms at end of two weeks of active treatment ...
... treatment may target hunger at its source, another uses ... stomach and suppress hunger and a third explores the ... Initial results from all these studies were reported at ... in San Francisco, Calif. (Logo: ...
Cached Medicine Technology:Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 2Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 3Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 4Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 5Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 6Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia 7No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 2No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 3No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 4No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 5No Pain, No Gain: Weight Loss, Disc Disease Interventional Radiology Treatments Coming 6
(Date:7/5/2015)... ... July 05, 2015 , ... Doctors at the Swedish Cancer Institute in ... one day change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just ... Researchers report that five mesothelioma patients treated with 25Gy of radiation over five days ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... the solar industry’s leading recognition of technical sales expertise from the North American ... Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established national ...
(Date:7/3/2015)... ... 03, 2015 , ... Scientists at several top US cancer centers believe they ... exposure. Click here to read the complete story , just posted on the ... Sinai Medical Center, and New York University exposed mice with a mutation on the ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... Health researchers have received nearly $13 million from the ... for victims of terrorist attacks, wartime use of toxic ... in these studies will be ,mustard gas, (sulfur mustard) ... is that they are designed to provide rescue treatments," ...
... -- In findings with major implications for the genetics of ... Center (BIDMC) and two other science teams in New York ... networks and showed how it may work to drive cancer ... 14 in the journal Cell describe aspects of ...
... times could cause men to seek more sexual partners, giving ... Gillath, a social psychology professor at the University of Kansas. ... when faced with a threatening environment, according to sexual selection ... think about their own death, which mimics conditions of "low ...
... a five year project with a $2 million ceiling ... the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined ... to prevent the acquisition of HIV and Herpes Simplex ... and acceptable, this combination of products would provide women ...
... (HealthDay News) -- Materialistic couples may have more money, ... a new study. Researchers have found that ... on couples, happiness and stability. In conducting the ... completed by more than 1,700 married couples across the ...
... have new avenues for scientific interaction, following a cooperation ... the government of Singapore. The agreement will allow Singapore ... It also means that EMBO workshops and lectures can ... agreement of its kind between EMBO, EMBC and Singapore. ...
Cached Medicine News:Health News:National Jewish Health researchers awarded $13 million to evaluate treatments for toxic gases 2Health News:Researchers discover hidden genetic influence on cancer 2Health News:Researchers discover hidden genetic influence on cancer 3Health News:Researchers discover hidden genetic influence on cancer 4Health News:Researchers discover hidden genetic influence on cancer 5Health News:Permanently dismal economy could prompt men to seek more sex partners 2Health News:USAID awards cooperative agreement to CONRAD for multipurpose prevention study 2Health News:Couples Can Pay a Price for Materialism 2Health News:Scientists in Singapore and Europe to collaborate 2
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Desmarres Retractor Size 4...
Medicine Products: